Login / Signup

Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.

Masaki ShimizuMao MizutaNami OkamotoTakahiro YasumiNaomi IwataHiroaki UmebayashiYuka OkuraNoriko KinjoTomohiro KubotaYasuo NakagishiKenichi NishimuraMariko MohriMasato YashiroJunko YasumuraHiroyuki WakiguchiMasaaki Mori
Published in: Pediatric rheumatology online journal (2020)
TCZ could modify the clinical and laboratory features of s-JIA-associated MAS. When evaluating the s-JIA patients while treated with TCZ, it is not applicable to use MAS classification criteria. Care must be taken to not underdiagnose MAS based on the MAS classification criteria.
Keyphrases